A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT ID: NCT04129710
Last Updated: 2021-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2020-01-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
NCT05549284
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04481815
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04934579
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT05564052
R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty
NCT04120350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I-MRE
Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
Rituximab 375 mg/m2 conventional infusion d1.Etoposide 250 mg/m2 over 3 hours on day3.
Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.
Ibrutinib
Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
Methotrexate
Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Rituximab
Rituximab 375 mg/m2 conventional infusion on day 1
Etoposide
Etoposide 250 mg/m2 over 3 hours on day3
PEGylated recombinant human granulocyte colony
PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
L-MRE
Oral lenalidomide 25mg/day (starting dose) between days 4 and 24 of each cycle for six cycles.Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
Rituximab 375 mg/m2 conventional infusion d1.
Etoposide 250 mg/m2 over 3 hours on day3.
Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.
Lenalidomide
Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
Methotrexate
Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Rituximab
Rituximab 375 mg/m2 conventional infusion on day 1
Etoposide
Etoposide 250 mg/m2 over 3 hours on day3
PEGylated recombinant human granulocyte colony
PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
MRE
Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
Rituximab 375 mg/m2 conventional infusion d1.
Etoposide 250 mg/m2 over 3 hours on day3.
Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.
Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time will be randomly allocated to the Experimental groups.
Methotrexate
Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Rituximab
Rituximab 375 mg/m2 conventional infusion on day 1
Etoposide
Etoposide 250 mg/m2 over 3 hours on day3
PEGylated recombinant human granulocyte colony
PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ibrutinib
Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
Lenalidomide
Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
Methotrexate
Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Rituximab
Rituximab 375 mg/m2 conventional infusion on day 1
Etoposide
Etoposide 250 mg/m2 over 3 hours on day3
PEGylated recombinant human granulocyte colony
PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Men and woman who are 18-75 years old on the day of consenting to the study.
3. Histologically documented PCNSL and histologically documented systemic diffuse large B-cell lymphoma (DLBCL).
4. Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL
5. All patients need to have received at least one prior CNS directed therapy. There is no restriction on the number of recurrences.
6. Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 21 days prior to study registration.
7. Participants must have an ECOG performance status of 0-3.
8. Participants must have adequate bone marrow and organ function shown by:
1. Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L
2. Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 21 days prior to study registration
3. Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration
4. International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal
5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal
6. Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome.
7. Serum creatinine ≤ 2 times the upper limit of normal
9. Woman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.
10. Patients must be able to tolerate MRI/CT scans.
11. Participants must have recovered to grade 1 toxicity from prior therapy.
12. Participants should be able to submit up to 20 unstained formalin-fixed, paraffinembedded (FFPE) slides from the initial tissue diagnosis prior to study registration for confirmation of diagnosis and correlative studies
13. NOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial.
Exclusion Criteria
2. Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy.
3. Patient has received external beam radiation therapy to the CNS within 21 days of the first dose of the study drug.
4. Patient requires more than 8 mg of dexamethasone daily or the equivalent
5. Patient has an active concurrent malignancy requiring active therapy
6. The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first Patient is allergic to components of the study drug.
7. Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug. Low molecular weight heparin is allowed. Patients with congenital bleeding diathesis are excluded.
8. Patient is taking a drug known to be a moderate and strong inhibitor or inducers of the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers for at least two weeks prior to starting the study drug.
9. Patient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of \> 5 mg/day or prednisone or the equivalent. Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug.
10. Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening,
11. Patient has a known bleeding diathesis (e.g. von Willebrand"s disease) or hemophilia.
12. Patient is known to have human immunodeficiency virus (HIV) infection.
13. Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests.
14. Patient is known to have an uncontrolled active systemic infection.
15. Patient underwent major systemic surgery ≤ 4 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug.
16. Patient is unable to swallow capsules or has a disease or condition significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction.
17. Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject"s safety or put the study outcomes at undue risk.
18. Women who are pregnant or nursing (lactating), where pregnancy is defined as a state of a female after conception until the termination of gestation, confirmed by a positive serum hCG laboratory test of \> 5 mIU/mL (See section on Pregnancy and Reproduction)
19. Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion)
20. The patient is unwell or unable to participate in all required study evaluations and procedures
21. Known hypersensitivity to ibrutinib, thalidomide or lenalidomide
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
Fujian Medical University Union Hospital
OTHER
RenJi Hospital
OTHER
Shanghai Tong Ren Hospital
OTHER
Shandong Provincial Hospital
OTHER_GOV
Cancer Hospital of Guangxi Medical University
OTHER
Sir Run Run Shaw Hospital
OTHER
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Yinzhou Hospital Affiliated to Medical School of Ningbo University
OTHER
Zhejiang University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China/Zhejiang Province, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I2019001413
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.